VectorY Therapeutics, a gene therapy biotech company, has announced a collaboration with Wageningen University to develop baculovirus-based technologies for the production of safe and affordable AAV gene therapies.
One of the most important challenges for the gene therapy industry is to develop robust and scalable processes that yield safe therapies. VectorY, together with Wageningen University, is making a strategic investment in these therapies, aiming to develop a production platform capable of manufacturing safe products at a lower COGS. The collaboration is hoped to improve the medical and economical feasibility of gene therapy for diseases that affect larger patient populations.
The Bioprocess Engineering and Virology Groups at Wageningen University and VectorY Therapeutics will work together on two projects. One will use the molecular toolbox to generate stable baculovirus genome seeds for AAV production at large scale. The second will focus on the design and evaluation of an intensified and scalable baculovirus production process in bioreactors using bioprocess technologies.
“We are very pleased to be collaborating with VectorY to develop proprietary, next generation AAV expression systems and industry-leading bioprocessing capabilities”, said Monique van Oers, Professor of Virology, Wageningen University.
“We are honoured to partner with Wageningen University, a significant pioneer in the Baculovirology and Bioprocessing field. This partnership will further strengthen VectorY’s proprietary AAV production technologies for the development of Next Generation Gene Therapies”, added Alexander Vos, CEO VectorY Therapeutics.
